Nektar Therapeutics (NASDAQ:NKTR) Shares Bought by Cwm LLC

Cwm LLC grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 4,544.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,524 shares of the biopharmaceutical company’s stock after purchasing an additional 103,252 shares during the period. Cwm LLC owned about 0.06% of Nektar Therapeutics worth $72,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Two Sigma Securities LLC boosted its holdings in Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 9,958 shares during the period. Harvest Investment Services LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at about $27,000. US Asset Management LLC purchased a new position in shares of Nektar Therapeutics in the 4th quarter valued at about $31,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Nektar Therapeutics during the first quarter worth about $41,000. Finally, ProShare Advisors LLC grew its position in shares of Nektar Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 50,277 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 16,543 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NKTR. HC Wainwright raised their target price on shares of Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. Jefferies Financial Group raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. BTIG Research increased their target price on Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a report on Monday, May 12th. Finally, Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.33.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $22.96 on Friday. The firm’s fifty day moving average price is $18.44 and its 200 day moving average price is $13.83. Nektar Therapeutics has a 12 month low of $6.45 and a 12 month high of $37.38. The company has a market capitalization of $284.93 million, a price-to-earnings ratio of -2.39 and a beta of 0.95.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The company had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. During the same quarter in the prior year, the company earned ($2.70) EPS. As a group, sell-side analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.